One Study Down, Three To Go On Animas’ First-Gen Artificial Pancreas Project
This article was originally published in The Gray Sheet
Executive Summary
Following a successful feasibility study, the J&J unit still has multiple clinical milestones to hit before it can put its closed-loop diabetes treatment system up for market approval.
You may also be interested in...
Research In Brief
Recent data and study announcements in cardiac, neuro and diabetes.
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.
Research In Brief
Artificial pancreas feasibility, computed tomography cancer risk documentation and more data updates.